Breast Cancer

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

Hope S. Rugo, MD

- Breast Cancer, SABCS 2017

Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy. [ Read More ]

Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation

Phoebe Starr

December 2017, Vol 7, No 12 - Breast Cancer, ESMO Highlights

For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase (PI3K) inhibitor in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer. The phase 3 study LORELEI compared neoadjuvant therapy with letrozole plus placebo versus letrozole plus taselisib, a PI3K inhibitor, in this patient population. [ Read More ]

MONARCH 3: Adding Abemaciclib to an Aromatase Inhibitor Improves Outcomes in Metastatic Breast Cancer

Phoebe Starr

December 2017, Vol 7, No 12 - Breast Cancer, ESMO Highlights

The addition of the cyclin-dependent kinase (CDK)4/CDK6 inhibitor abemaciclib (Verzenio) to an aromatase inhibitor improved progression-free survival (PFS) over aromatase inhibitor monotherapy in women with hormone receptor (HR)-positive, HER2-­negative advanced breast cancer, according to an interim analysis of the phase 3 MONARCH 3 clinical trial presented at the 2017 European Society for Medical Oncology (ESMO) Congress. The study was also re­cently published in the Journal of Clinical Oncology. [ Read More ]